See more : Nama Chemicals Company (2210.SR) Income Statement Analysis – Financial Results
Complete financial analysis of Asarina Pharma AB (publ) (ASAP.ST) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Asarina Pharma AB (publ), a leading company in the Biotechnology industry within the Healthcare sector.
- Infinite Networks Corporation (INNX) Income Statement Analysis – Financial Results
- Nippon Ichi Software, Inc. (3851.T) Income Statement Analysis – Financial Results
- CD International Enterprises, Inc. (CDIIQ) Income Statement Analysis – Financial Results
- Rogers Communications Inc. (RCI-B.TO) Income Statement Analysis – Financial Results
- Oncopeptides AB (publ) (ONPPF) Income Statement Analysis – Financial Results
Asarina Pharma AB (publ) (ASAP.ST)
About Asarina Pharma AB (publ)
Asarina Pharma AB (publ), a biotech company, researches and develops pharmaceutical products. Its flagship product is Sepranolone, which is used for the treatment of menstrual migraine and Tourette syndrome. The company was formerly known as Umecrine Mood AB and changed its name to Asarina Pharma AB (publ) in 2016. Asarina Pharma AB (publ) was incorporated in 2005 and is based in Solna, Sweden.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 423.00K | 406.00K | 388.00K | 89.00K | 0.00 | 0.00 | 31.00K |
| Gross Profit | -423.00K | -406.00K | -388.00K | -89.00K | 0.00 | 0.00 | -31.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 6.49M | 7.29M | 29.92M | 63.75M | 63.45M | 39.03M | 22.99M |
| General & Administrative | 0.00 | 3.09M | 2.91M | 7.44M | 5.90M | 6.19M | 3.46M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.72M | 3.09M | 2.91M | 7.44M | 5.90M | 6.19M | 3.46M |
| Other Expenses | 0.00 | 4.31M | 5.45M | 10.21M | 11.89M | 6.37M | 1.67M |
| Operating Expenses | 14.65M | 14.69M | 38.28M | 81.41M | 81.23M | 51.60M | 32.53M |
| Cost & Expenses | 14.65M | 14.69M | 38.28M | 81.41M | 81.23M | 51.60M | 32.53M |
| Interest Income | 62.00 | 14.00K | 6.00K | 6.00K | 7.00K | 22.00K | 251.00K |
| Interest Expense | 0.00 | 298.00K | 395.00K | 201.00K | 252.00K | 171.00K | 25.00K |
| Depreciation & Amortization | 423.00K | 406.00K | 388.00K | 89.00K | -250.00K | 31.00K | 31.00K |
| EBITDA | -14.22M | -14.12M | -37.90M | -82.70M | -81.48M | -51.42M | -28.40M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -14.64M | -14.69M | -38.28M | -81.41M | -81.03M | -51.60M | -32.53M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 62.00K | -141.00K | -13.00K | -1.59M | 2.16M | 2.00K | 226.00K |
| Income Before Tax | -14.58M | -14.83M | -38.30M | -82.99M | -78.88M | -51.59M | -32.31M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 1.75M | -1.55M | -6.64M | -7.74M | -7.80M | -7.57M | -4.01M |
| Net Income | -12.83M | -13.28M | -31.66M | -75.26M | -71.08M | -44.03M | -28.30M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.57 | -0.71 | -1.69 | -4.02 | -4.30 | -2.75 | -3.97 |
| EPS Diluted | -0.57 | -0.71 | -1.69 | -4.02 | -4.30 | -2.75 | -3.97 |
| Weighted Avg Shares Out | 22.64M | 18.79M | 18.74M | 18.70M | 16.54M | 16.04M | 7.13M |
| Weighted Avg Shares Out (Dil) | 22.64M | 18.79M | 18.74M | 18.70M | 16.54M | 16.04M | 7.13M |
Source: https://incomestatements.info
Category: Stock Reports